Drug profile · INN
daclizumab
ZENAPAX
daclizumab (ZENAPAX) is a interleukin-2 receptor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — daclizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
daclizumab (ZENAPAX) is a interleukin-2 receptor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-2 receptor inhibitor
Primary target: Interleukin-2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daclizumab?
daclizumab (ZENAPAX) is a interleukin-2 receptor inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daclizumab?
ZENAPAX is a marketed brand name for daclizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daclizumab?
daclizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.